Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Spyre Therapeutics (SYRE) has drawn interest recently as investors look at a clinical stage biotech with no current revenue, a reported net loss of US$118.381 million, and a focus on inflammatory bowel disease treatments. See our latest analysis for Spyre Therapeutics. At a share price of US$33.24, Spyre Therapeutics has delivered a 47.93% 90 day share price return and a 61.20% 1 year total shareholder return. This suggests that recent momentum has been building as investors reassess the risk and potential of its inflammatory bowel disease pipeline. If this kind of biotech rerating has your attention, it could be a good moment to scan other healthcare stocks that might fit a similar risk and reward profile. With a clinical stage pipeline, zero current revenue and a share price at US$33.24, the key question is whether Spyre Therapeutics is still trading below its potential or if the market is already pricing in future growth. Spyre Therapeutics is trading on a P/B of 8.6x, a
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by Stifel Nicolaus from $70.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms [Seeking Alpha]Seeking Alpha
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 3/5/26 - Form EFFECT
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SYRE's page on the SEC website